In Tuesday’s Wall Street session, Processa Pharmaceuticals Inc (NASDAQ:PCSA) shares traded at $0.27, up 4.57% from the previous session.
PCSA stock price is now -41.40% away from the 50-day moving average and -74.76% away from the 200-day moving average. The market capitalization of the company currently stands at $1.42M.
With the price target of $8, H.C. Wainwright recently initiated with Buy rating for Processa Pharmaceuticals Inc (NASDAQ: PCSA).
In other news, Yorke Justin W, Director bought 12,400 shares of the company’s stock on Jan 27 ’25. The stock was bought for $9,889 at an average price of $0.80. Upon completion of the transaction, the Director now directly owns 12,400 shares in the company, valued at $3348.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 27 ’25, Chief Executive Officer Ng George K bought 87,200 shares of the business’s stock. A total of $69,542 was incurred on buying the stock at an average price of $0.80. This leaves the insider owning 87,200 shares of the company worth $23544.0. A total of 11.36% of the company’s stock is owned by insiders.
During the past 12 months, Processa Pharmaceuticals Inc has had a low of $0.21 and a high of $3.10. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 1.22, and a quick ratio of 1.22. The fifty day moving average price for PCSA is $0.46096 and a two-hundred day moving average price translates $1.07018 for the stock.
The latest earnings results from Processa Pharmaceuticals Inc (NASDAQ: PCSA) was released for 2024-12-31.
